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CHAPTER 1.  INTRODUCTION AND LITERATURE REVIEW 
The primary goal of any  cancer radiation therapy is to kill tumor cells by 
introducing lethal doses of radiation to the cancerous tissues, ideally to every cancer cell. 
However, there are many drawbacks to the conventional type of radiation therapy. 
Traditional radiation therapy involves a beam of radiation (usually X-rays or soft gamma-
rays) that is aimed at the tumor location from outside the body. Although this type of 
radiation is very effective at killing cancer cells, it is also very proficient at killing healthy 
cells.  Therefore, due to the type of radiation used in  conventional therapy and the 
relatively nonspecific manner in which the radiation is delivered, healthy tissues  are 
damaged and the patient's whole body dose of radiation is often very high. In addition, 
the treatment is generally repeated several times, and there is still no guarantee that every 
cancer cell received a lethal dose of radiation. 
An ideal type of radiation therapy for cancer would preferentially kill all tumor 
cells, while not seriously damaging healthy tissues.  Incredibly, the concept for this type 
of therapy has existed for over fifty years in a reaction known as boron neutron capture. 
The reaction involves a '°B atom which when bombarded by a thermal or epithermal (i.e., 
low energy) neutron, promptly disintegrates into  a 'Li nucleus and a stripped helium 
nucleus, otherwise known as an alpha particle. An average of 2.34 MeV of energy is 
released per event within a distance of 10 microns.  From this reaction was developed 
boron neutron capture therapy (BNCT), an alternative form of radiation therapy. 2 
The method of BNCT as a cancer treatment therapy involves loading boron-10 
atoms into tumor cells and subsequently irradiating the area with thermal or epithermal 
neutrons. This type of therapy is seen as being primarily used for inoperable tumors, 
especially in the brain where the sparing of healthy tissue is of extreme importance. In 
order for BNCT to be successful, a critical amount of '°B and a sufficient number of 
thermal or epithermal neutrons must be delivered to individual  tumor cells. 
BNCT research at Oregon State University (OSU) with the collaboration of 
researchers at Oregon Health Sciences University (OHSU) has focused on cancers of the 
endocrine system, specifically pituitary tumors.  This research involves the in vitro 
irradiation of boron-infused rat pituitary  cancer cells, with subsequent reculture and 
observation. This study addresses the importance of the cell survival  curve as a means 
of measuring the response of the cells to varying doses of radiation, and successfully 
demonstrates the classic response of mammalian cells when exposed to varying doses of 
6°Co radiation. 
Topics presented will include a brief background and history of BNCT, including 
some treatment possibilities and future considerations, an explanation of cell survival 
curves and their role in radiobiologic studies, and the application of cell survival curves 
in the OSU BNCT program. 
1.1 BNCT: Past, Present and Future 
Enrico Fermi and his associates first noted in 1934 that if neutrons were slowed 
by passage through paraffin or water, they were more likely to be absorbed by atomic 
nuclei [1,2,3,4]. On December 10, 1934 the first observation of charged particles from 3 
slow neutron irradiation was made at Cambridge University [5]. When these neutron 
capture reactions became known in the United States, it was proposed that they be applied 
to radiation therapy by the selective uptake of a suitable isotope into a patient's tumor, 
followed by slow-neutron irradiation of the tumorous tissue [6].  Although these nuclear 
reactions were found to occur with 1°B, 7Li and nitrogen, boron  was the chosen element 
since it not only could be incorporated into various tumor-affinitive drugs, but was also 
the most likely to react with a neutron in a slow neutron field [7]. By using radium mixed 
with a beryllium powder as a neutron source, the first radiobiologic studies using the 't 
neutron reaction were performed at the University of Illinois in 1938 [8].  During the next 
few years there were various claims of the reduced viability of mouse tumor transplants 
and the regression of mouse sarcomas after exposure to boric acid and subsequent in vitro 
slow neutron irradiation [8]  . 
After World War II, circumstances in the United States  were appropriate for 
studies in radiobiology and medical physics to begin  at institutes such as Brookhaven 
National Laboratory (BNL), established by the Atomic Energy Commission (AEC) for 
primarily non-military nuclear physics research [9].  These studies included a renewed 
interest in neutron capture therapy. In August of 1950 the Brookhaven Graphite Research 
Reactor (BGRR) was commissioned, and soon afterwards plans began for an irradiation 
facility to be built at the top of the BGRR. This facility would include a neutron port with 
a major intermediate (epithermal) energy component in the neutron beam specifically for 
BNCT [9]. Beginning in 1951, some patients with glioblastoma multiforme were referred 
to Brookhaven for BNCT at the irradiation facility of the BGRR [9]. 4 
The first patient was irradiated at the BGRR on February 15, 1951, just six months 
after the BGRR was commissioned [9]. Although no serious side effects from the BNCT 
were seen in the first set of ten patients, the therapy itself was largely unsuccessful. The 
second and third BNCT trials still showed little or no therapeutic efficacy, with a median 
post-therapy survival time of 96 days.  The researchers concluded that the boron 
compounds did not concentrate and persist in the tumor cells and the thermal neutrons did 
not penetrate to adequate depths [10]. 
In 1958, research began at the Massachusetts Institute of Technology (MIT) to 
identify a '°B carrier that yielded more favorable tumor:brain boron concentration ratios 
[9]. A p-carboxyl derivative, which showed  a 2.5-9.0 tumor-to-tissue ratio between 15 
minutes and 3 hours after intraperitoneal injection,  was selected as a '°B carrier in 16 
patients treated with BNCT at the MIT reactor.  This outcome, like others,  was 
unsatifactory in that the median survival time was only six months [11]. 
In these early clinical  trials with BNCT, it was discovered that  a major 
complication was radiation damage to the cerebral vasculature.  This was due in part to 
the fact that no technique existed that was fast enough to allow estimation of a patient's 
blood '°B concentration in planning the irradiation time [9].  In addition, few boron-
containing compounds existed that would enter the glioma freely, while not crossing the 
blood-brain barrier. Boron compounds specifically for thispurpose were first synthesized 
in the 1960s from polyhedral boranes [12,13].  After studies demonstating the 
applicability of these types of compounds, sodium  mercaptoundecahydrododecaborate 
(commonly known as BSH) was selected for a trial of BNCT for brain tumors in Japan 5 
[9]. The first BNCT irradiation in Japan took place in August of 1968 [14]. Since that 
time there have been reports of excellent clinical results in some malignant glioma 
patients treated with BNCT in Japan [9]. One man treated with BNCT at age 50 in 1972, 
was alive and neurologically stable in the spring of 1990 (Hatanaka 1990, unpublished). 
Even with this and other successes, the western world is reluctant to adopt the Japanese 
techniques in favor of refining and improving  some of the methods.  Many of the 
techniques used in Japan tend to require many hours of irradiation and involve some 
trauma to the skull of the patient. 
Another area of special interest involves the development ofcompounds that might 
serve in the treatment of malignant melanoma [10].  Melanomas tend to incorporate 
elevated levels of phenylalanine, an essential amino acid,  into the pigment melanin. 
Researchers are therefore attempting to develop phenylalanine derivatives that contain 
boron in hope that the melanoma cells would incorporate the boronylated compound [10]. 
A related technique relies on the fact that malignant  cells tend to uptake 
nucleosides, the building blocks of DNA, at a faster rate than do normal cells [10]. One 
key advantage of concentrating the boron in the nucleus of the cell is that it would greatly 
enhance the destructive effects of the a-particles [10]. 
The use of antibodies as "guided missiles"  is another approach to the delivery 
of 'B. Antibodies are proteins that have the ability to recognize specific antigens on the 
surfaces of tumor cells [10]. Monoclonals, a highly specialized form of antibodies, were 
quickly recognized as having the greatest potential in boron delivery for a variety of 
tumor-killing agents [10]. 6 
It has also been discovered that heavy water, or D20 may actually improve the 
mechanism of BNCT through partial deuteration of tissues being considered for the 
therapy.  In preliminary experiments, brain water deuteration has  allowed improved 
thermal neutron transmission with reduced capture y ray doses due to the lower cross 
section of D20 as compared to H2O [15]. This method is thought to have promise for 
deep-seated or wide-spread tumors. 
Current BNCT research focuses mainly  on identifying pharmacologically and 
radiobiologically suitable boron carriers.  One of the most recent advances in boron 
carriers is being researched at OHSU and OSU for the treatment of pituitary tumors. The 
carrier molecule is a hypothalamic polypeptide releasing  hormone known as ovine 
corticotrophin releasing hormone (oCRH). A 1013,0 carborane cage (synthesized, purified 
and supplied by Professor M. Frederick Hawthorne,  Department of Chemistry and 
Biochemistry, UCLA) is then attached to the oCRH using polypeptide bonds. [16] 
1.2  The Boron Neutron Capture Reaction 
Boron neutron capture therapy is based  on the reaction that occurs when '°B 
(stable) is bombarded with a thermal neutron to yield highly  ionizing stripped down 
helium nuclei (a-particles) and 'Li nuclei. 
4He +7Li + 2.79 MeV (6%) 
, 
'°B + nth (0.025 eV)-4[1113]. 
4He +7Li + 0.48 MeV y + 2.31 MeV (94%) 7 
From these two reaction pathways, it is possible to note the high energy release 
of 2.79 MeV 6% of the time and 2.31 MeV 94% of the time, with a weighted average 
energy emission of 2.34 MeV per capture reaction. As can be noted, most (83%) of the 
energy released can be attributed to the 7Li nucleus and the a-particle, while the 
remaining 17% of the energy released is due to a prompt y-ray.  Since the particles 
released are high LET (Linear Energy Transfer), they give rise to closely spaced, highly 
ionizing events which destroy a wide variety of biologically active molecules including 
DNA, RNA and proteins [17]. Figure 1-1 illustrates the mechanics of this reaction as it 
occurs inside of a tumor cell. 
et a +2) 
Figure 1-1  BNCT Reaction Inside A Tumor Cell
 
A '°13 nucleus generating an a-particle and a 7Li nucleus, both high LET particles capable of killing the
 
cell.
 8 
There are a number of nuclides with a high propensity to absorb thermal neutrons 
(Table 1).  This property is known as the neutron cross section, symbolized as a, and is 
measured in barns (lb = oi -24cm2s. )  113 was chosen as the nuclide of choice for thefollowing 
reasons:  (a) it is nonradioactive, comprises 20% of all natural boron, and  is readily 
available, (b) the particles released are largely high LET, (c) unlike x-rays, a-particles do 
not require oxygen to enhance their biological effectiveness, which is particularly useful 
since a rapidly expanding tumor often outgrows its blood supply [10], and (d) '°B can be 
incorporated into a variety of radiobiologically and pharmacologically useful structures 
[17]. 
Table 1-1 Thermal neutron capture cross section values of potential nuclides for 
neutron capture therapy 
Nuclide  Cross-section (cr)t  Nuclide  Cross-section (cr)t 
'"Gd 3He  5,500  58,000 
6Li 
loB 
953  I"Gd  240,000
124F/f 3,837  400 
"3cd  20,000  1g  2000 '3SXe*  23su 2,720,000  678 149sm  24ipu 41,500  1,375 
IslEu  5,900  242Am*  8,000 
Indicates that the nuclide is radioactive
 
10-24 cm2)
 t Capture cross-sections are given in barns (lb = 9 
Table 1-2  Thermal neutron capture cross section values of normal tissue elements 
Element  Cross-section (a)t  Element  Cross-section (a)t 
H  0.332  N  1.75 
Na  0.536  P  0.19 
K  2.07  0  <0.0002 
Mg  0.069  S  0.52 
Ca  0.44  Cl  33.8 
C  0.0037  Fe  2.62
 
tCapture cross-sections are given in barns (lb = 10.24 cm2) 
Some nuclides of elements in normal tissues also tend to absorb thermal neutrons 
(Table 2). This poses a slight problem even though these elements have a cross section 
several orders of magnitude lower than boron. Two of these elements, hydrogen and 
nitrogen, are present in such high concentrations that their  capture neutrons contribute 
significantly to the total radiation absorbed dose [17].  This effect can be extremely 
detrimental to the delicate vasculature of the brain.  It is possible to reduce this by 
ensuring the tumor have extremely high '°B concentrations so that the neutron fluence (n­
cm-2) can be kept relatively low, thereby maximizing the '°B(n,a)'Li reaction while the 
(n,p) reaction with nitrogen [14N0,014c] and the (n,y) reaction with hydrogen ['H(n,y)2H] 
can be kept to a minimum [17].  It has been estimated that for '°B in tumor tissue at 
concentration of 50 peg, 86% of the dose would be from the '°B capture reaction [17]. 
The necessary concentration has also been stated as 109 (1 billion) '°B atoms per cell, a 
number which was derived from experiments performed up to two decades ago, which 
defined the "minimal tumoricidal concentration" of '°B in wet tissue samples to be 15-50 10 
tg/g, [10,17] but should not exceed 100 peg to avoid the self-shielding  effect of boron 
at high concentrations [15]. 
13 Boron Quantification Techniques 
In order for BNCT to be successful, it is necessary to be able to quantitate the 
amount of boron in the tumor cells. Two techniques recently introduced are Inductively 
Coupled Plasma Atomic Emission Spectroscopy (ICP-AES) and  Inductively Coupled 
Plasma Mass Spectroscopy (ICP-MS). These methods are capable of measuring boron 
in samples with a precision of 3% at levels of 0.15 ppb, and a precision of 1% at higher 
levels [18].  The only drawback to methods such  as these is that there is no way to 
determine where in the cell the boron is located.  However, it is by far the most sensitive 
technique for measuring low levels of boron and some other elements. 
ICP-MS is the method used to quantify levels of boron in the cellular studies at 
OSU. This is in part due to the new facility locally available at the OSU College of 
Oceanography and Atmospheric Sciences. ICP-MS embodies two technologies, ArICP 
and quadrupole mass spectroscopy, each of which has existed for over three decades [19]. 
ArICP was best known as an emission source for multi-element spectroscopic analysis. 
Organic mass spectroscopy has shown  great successes by applying quadrupoles as the 
impetus to improved performance characteristics [19]. 
In ICP-MS samples are generally introduced in  aqueous solutions. Samples are 
then peristaltically pumped through a nebulizer which then breaks the sample into  an 
aerosol with droplets a few hundred gm in diameter. Since the maximum droplet size 
that can be completely desolvated, atomized and ionized in its course through the plasma 11 
is about 10i.tm, the aerosol is subsampled through a spray chamber. (This amounts to 
approximately 1% of the sample reaching the plasma, with the  rest being pumped to 
waste.) The plasma is lit by momentarily discharging a spark coil, which strips electrons 
from the gas entering the chamber, and reaches 10,000°C. The ions are then directed 
from the plasma into the quadrupole detection system, which consists offour parallel rods 
to which AC and DC voltages are applied.  Ions of a chosen charge-to-mass ratio 
preferentially oscillate in the plane parallel to the rods and strike the detector.  The 
voltages are set so that signals are resolved to 1  amu.  Signals reaching the electron 
multiplier are then amplified and sent to a multichannel analyzer and  processed by 
computer [19]. Due to the ingeneous ion extraction system, the relative ion count rates 
directly reflect the composition of the sample [20]. 
Complications occur when this technique is applied to biological tissue, primarily 
due to the "stickiness" of the cell membranes. Sample digestion is therefore necessary 
and is achieved through a method known  as closed vessel microwave digestion. 
However, unless sample digestion is complete,  a precipitate can form, causing lower 
values for the analyte concentration [21]. 
1.4 BNCF as a Treatment For Pituitary Tumors 
Pituitary tumors are a type of endocrine  cancer that because of certain 
characteristics make them excellent candidates for BNCT. Since the pituitary gland itself 
is approximately 1 cm in diameter, tumors of this organ tend to be less than 2 cm in 
diameter and very localized. In addition, the mechanism of '13 transport allows for 
increased specificity since each tissue of the endocrine system contains cellular membrane 12 
receptors which bind and internalize only appropriate releasing hormones. Therefore, 
specifically tagged molecules would be recognized and subsequently delivered  to the 
desired area. 
Although not always malignant, pituitary tumors comprise approximately 10-15% 
of all intracranial tumors [22]. These tumors, even when benign, generally cause large 
amounts of certain hormones to be released from the pituitary, and  are associated with 
such  disorders  as  acromegaly  (Growth  Hormone,  [GH]),  Cushing's  disease 
(Adrenocorticotropin Hormone, [ACTH]), and thyrotoxicosis (Thyroid Stimulating 
Hormone, [TSH]).  These disorders cause many physically distressing  symptoms; 
however, rarely are they fatal. 
The pituitary gland sits at the base of the brain in a small indentation of cranial 
bone called the sella tursica (see Figure 1-2). The anterior lobe of the pituitary gland 
(adenohypophysis) contains specific secretory cells for several vital hormones.  Directly 
above and connected to the pituitary is the hypothalamus, which is  responsible for 
secreting releasing hormones specific to each of the hormones produced in the pituitary. 
In order for a hormone to be released from the pituitary,  a secretory cell must 
successfully recognize and bind with its specific releasing hormone.  By "tagging" 
specific releasing hormones with '°13, it is possible to load boron very specifically into 
cells of the pituitary. 
Experiments to demonstrate the efficacy of this method  are being carried out at 
OSU in collaboration with researchers from OHSU. A synthetic "boronylated" releasing 13 
hormone was manufactured consisting of a 10B10 (ten-atom) carborane cage attached by 
way of polypeptide bonds to oCRH (ovine corticotropin releasing hormone). 
It should be noted that a fairly clear route for surgical removal  exists directly 
through the sphenoidal sinus, and has been successful.  However, BNCT allows for a 
completely specific and unintrusive removal. 
Although conditions resulting from pituitary tumors are generally more distressing 
than fatal, many other endocrine cancers, such as breast, prostate, pancreatic and adrenal, 
tend to be quite metastatic and often fatal.  It is therefore hoped that by studying the 
effects of BNCT on a typical endocrine tissue, i.e., pituitary cells, much  will be learned 
concerning other more lethal types of endocrine cancers. 
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CHAPTER 2.  CELL SURVIVAL CURVES 
2.1 Explanation and Purpose 
A cell survival curve describes the relationship between the radiation dose received 
and the fraction of cells that survive that dose.  Since the term "survival" can be 
interpreted in many different ways, it is necessary to clarify how it will be defined in this 
study.  Cell survival for certain differentiated cells, such as nerve, muscle, or secretory 
cells, can be described as loss of a specific function [1].  Survival for proliferating cells 
can be described as a loss of the ability to sustain successful mitotic activity. This loss 
of reproductive integrity is known  as reproductive death.  This ability is measured by 
whether or not a single cell (plated in vitro)  can develop into a large clone, or colony. 
(Since radiation-damaged cells  may struggle through a few mitoses, it is necessary to 
define a colony as a certain expected number of cells, given a length of time.) This is of 
particular interest when dealing with tumor cells, since if the cells are rendered incapable 
of reproduction, growth of the tumor will  cease.  Therefore this study will  use 
reproductive integrity, (or the loss thereof), as a measure of cell survival. 
Cell survival curves are generally limited  to proliferative cells, for it is the 
dividing cells of an organism that comprise the stem-cell compartment, and in whole-body 
radiation exposure whether or not the stem cells survive  determines the outcome of the 
individual [2].  Proliferative cells have a mean lethal dose of 2 Gy (200 rads), while a 
dose of 100 Gy (10,000 rads) is usually necessary to destroy the function of differentiated 
cells [1]. 17 
In order to develop a reasonable understanding of cell survival curves, it is useful 
to note the steps necessary to generate these curves in  an experimental situation. 
Established cell lines are almost always used in cell survival experiments, since many of 
the normal characteristics of the cells are well documented. 
Cells from an actively growing stock culture are generally removed from their 
growing surface, or "fanned," by use of the chemical  agent trypsin.  Trypsinization 
removes the cells by dissolving and loosening the cell membrane. It is possible to over­
trypsinize cells (noted by cell lysing), so the amount of time the cells are exposed to the 
trypsin is vital. The single cells are then suspended in an isotonic solution and counted 
using either a hemacytometer or an electronic counter. It is then possible to irradiate and 
subsequently seed plates with a known number of cells. The plates are then incubated 
for one to two weeks.  Generally, surviving cells will divide and form large colonies, 
while radiation damaged cells will not. The colonies  are then counted, and the number 
of colonies is compared to the number of cells plated. 
However, since some surviving cells (even those not exposed to radiation) do not 
divide and form colonies, it is necessary to calculate what is known as a plating efficiency 
(PE). This is done by plating a known number of cells onto a plate that is not exposed 
to radiation, incubating the plate under the same conditions as for the irradiated cells, and 
counting the surviving colonies.  These plates are generally used as the experimental 
controls. The plating efficiency (in percent) is therefore given by 
Colonies Counted x loo PE = 
Cells Seeded 18 
For example, if 200 cells were seeded (plated) and 140 survived to form colonies, the PE 
would be 70%. The plating efficiency then must be applied to each plate that has been 
irradiated in order to assess whether or not cell death is due to radiation damage or other 
factors. Other factors may include anything from poor growth medium, counting errors, 
or cell trauma through handling.  The surviving fraction (S) of cells from each of the 
irradiated plates is then given by 
Colonies Counted S = 
Cells Seeded x (PEI100) 
Therefore, if 1000 cells were seeded and 100 colonies counted (with  a 70% PE), the 
surviving fraction would be 0.14, or 14%. Ideally, to make colony counting less of a 
chore, experimenters generally try to grow no more than 200 colonies per plate. In order 
to achieve this, it is necessary to seed many more cells  at higher radiation doses as 
compared to lower doses. For example, say the PE is known to be 70% for a given cell 
line under certain experimental conditions.  In order to achieve 200 colonies (on  an 
unirradiated plate) it would be necessary to seed the plate with 285 cells. When plates 
are seeded prior to irradiation, a specific number of cells (depending on the amount and 
type of radiation administered) must be derived for each dose. The surviving fraction of 
cells for higher doses of radiation is often very low, and hundreds of thousands of cells 
are sometimes seeded to achieve 200 colonies. 
These surviving fractions are then plotted  on a log scale against radiation dose, and 
generally appear as illustrated in Figure 2-1. 19 
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Figure 2-1  Dose-Survival Curve for Mammalian Cells 
A typical low LET radiation survival curve illustrating the extrapolation number, n, the quasi-threshold 
dose, Dq, and the Do, (also known as D37). [3] 
From the shape of a survival curve it is possible to note several things pertaining 
to the radiosensitivity of the cells involved, for the shape of the curve varies depending 
on the type of radiation to which the cells are exposed. For sparsely ionizing radiation 
(x-rays or gamma rays), the curve starts out at lower doses as a straight line with a slope 
of nearly zero (see Figure 2-2). As theories that will be discussed shortly will attain, this 
is due to the ability of cells to withstand higher doses of low LET radiation, (as compared 
to high LET radiation). As dose increases, the curve bends, extending over a few Gy (a 
few hundred rads). At high doses the curve straightens out and the surviving fraction can 
be measured as an exponential function of dose.  For more densely ionizing radiation 
(high LET particles such as a-particles or low energy neutrons), a survival curve is 20 
effectively a straight line from the origin. Survival in this case can therefore be 
approximated as an exponential function of dose for the entire curve [1]. 
While qualitatively assessing survival curves is relatively simplistic, describing the 
shape of survival curves based on the effects of radiobiological events is another matter. 
2.2 Methods of Intetpretation 
Cell survival curves display the underlying relationship between radiation dose and 
biological effect.  In order to interpret the results of these curves, both mathematical 
formulae and theoretical  mechanics of action have been derived.  Cell inactivation 
theories developed as a result of the known stochastic nature of energy absorption in 
biological material [3]. The most well-known of these theories is the Target Theory, 
which can be applied to both exponential and shouldered survival curves. Other theories 
include the Theory of Dual Radiation Action, the "Molecular Theory" of Cell Inactivation, 
and repair models (Q-Repair). Since it is not actually known which of these theories, if 
any, is correct, each of them will be discussed briefly.  First, however, an overview of 
what information can be gained from survival  curves is necessary. 
The abbreviations Do, Dq, and n (see Figure 2-1) are often used as a means of 
quantifying cell radiosensitivity. The term Do (often known as D3) is the dose required, 
within the exponential region, to reduce the fraction of cells surviving from some value 
f to elf (-0.37f, hence the name); Dq (known as the quasi-threshold dose) refers to the 
width of the shoulder and corresponds to the value of the intercept of the extrapolated 
straight portion of the curve at the surviving fraction of 1.0;  n is the extrapolation value 
of the intercept from the straight portion of the curve on the survival axis at zero dose. 21 
The shapes of survival curves and the changes exhibited due to differing types of 
radiation have been a basis for constructing various mathematical  models and theories 
concerning the biophysical mechanisms involved in cell killing, or inactivation processes. 
2.2.1.  Target Theory 
The conceptual basis of target theory rests on the assumption that the observed 
biological effects are due to a single energy absorption event in the discrete target volume 
within a cell [3]. The target may be a whole cell, part of a cell, or a critical organ [4]. 
The assumption of a discrete sensitive volume, or target that must be inactivated to create 
the desired effect (whether or not it is valid), has been a dominant theme in radiobiology 
from the 1920s up to the present [3].  Since mammalian cell survival curves are of two 
shapes (exponential or sigmoid), there are two slightly different derivations. 
Exponential Curves 
The dose delivered is defined in terms of the number of inactivating hits per unit 
volume of irradiated material.  In the sensitive volume, if the average hits per target 
(distributed randomly) is A, then the fraction of targets receiving exactly n hits can be 
represented by the Poisson formula 
e-A A"
 
n!
 
If it is assumed that cell inactivation occurs following a single hit to the target, 
a biological statement of the survival fraction can be represented as 22 
S = e' 
If Do is the dose required to reduce cell survival from 1 to lie, and which gives, 
on average, one lethal event per target, then 
S =  ne-DID° 
Target theory in this regard seems fairly abstract, and mathematical. Biologically, 
however, it is an extremely complex process, and many factors, such as the differing 
levels of complexity of each of the cell structures, must be considered. If each of these 
targets is considered individually, a new formula can be derived, but still without 
information with regard to target size. 
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Figure 2-2  High LET vs Low LET Survival Curves for Mammalian Cells
 
Curve II illustrates a typical low LET radiation (X-rays in this case) shouldered survival curve. Curve I
 
is exponential form the origin, typical of high LET radiation such as neutrons.
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Shouldered Survival Curves 
For a single-hit, multitarget model, the general formula for a cell survival curve 
with an initial slope of zero, a shoulder, and an exponential region is 
S = 1-(1-eDIDT 
where m = the number of independent targets per cell requiring a hit for the cell to be 
inactivated, and assuming each of the m targets must be hit once for cell inactivation to 
occur. Mathematically, this formula works very well; however, physiologically  m seems 
to depend heavily on the state of the cell, its stage in the cell cycle, and the conditions 
of irradiation [3]. 
In general, target theory has created a framework from which attempts are made 
to interpret the shapes of survival curves in biophysical terms. However, since the cell's 
metabolic state and repair processes are not taken into consideration, it seems nearly 
impossible to make a biological translation of which mechanisms are responsible for cell 
inactivation versus cell survival. 
2.2.2. The Theory of Dual Radiation Action 
This model is based on the concept that it takes more than one hit per target to 
induce inactivation. This theory was developed by Kellerer and Rossi [5] to explain the 
relationship between RBE (Relative Biological Effectiveness) and radiation dose for high 
LET radiation. They arrived at the equation of the form 24 
S = egD-0°2 
where a refers to the probability of an effect being caused by  a single track, (hit), while 
(3 refers to the probability that an effect was caused by two tracks. This gives a survival 
curve which has a shoulder but which is continuously bending. Although this method of 
interpretation has been shown to work well in certain circumstances, the general validity 
of this theory has been questioned. However, recent studies involving irradiation with 
deuteron pairs versus single deuterium ion beams have shown that in fact greater cell 
killing does occur when irradiating with ion pairs [3]. 
2.2.3. The "Molecular Theory" of Cell Inactivation 
The concept of this theory, developed by Chadwick and Leenhouts  [6], is also 
based on the idea that more than one hit per target is necessary for cell inactivation. 
However, the "Molecular Theory"  assumes that all cell inactivation is caused by the 
induction of unrepaired double-strand breaks in DNA [3]. With low LET radiation, it is 
thought that the breaks can result from either one hit or two separate hits near one another 
on the complementary strands of DNA. From these assumptions a relationship identical 
to that of dual radiation action gives 
S = eaD-P2 
where here a refers to a single-strand break inactivation and 0 to a double-strand break 
inactivation. It is thought that for low LET radiations and doses greater than a few Gy, 
cell inactivation will occur predominately by single-strand  breaks that, if repaired 
improperly, will become double-strand breaks. (Generally, it is thought that induction of 25 
double-strand breaks from a single event is cause for cell inactivation.) Although the 
equation derived in this theory (and dual radiation) allows for a better fit to cell survival 
data, the basic assumptions to the "Molecular Theory" have also recently been open to 
doubt. 
2.2.4.  Repair Models 
The repair theory for shouldered curves was first introduced by Powers [7].  It also 
involves the concept that cell killing is due to a multiplicity of ionizing events, only 
viewed in a slightly different way. According to this theory one damaging event can kill 
the cell if it is not repaired, or somehow rendered incapable of repair over a certain length 
of time [3]. From studies with ultrasoft X-rays, Goodhead et al. [8] proposed that for low 
LET radiation, lethal lesions are the result of small amounts of energy (up to 300 eV) in 
a few nm as a result of a one-hit action. The number of lesions produced is proportional 
to dose and the efficiency of production is proportional to LET [3]. The shoulder of the 
survival curve is the result of some of the lesions being repaired. This repair process is 
dose-dependent and is saturated at higher doses. This explanation of the shoulder of 
survival curves is also known as Q-repair. From repair models of this type, it is possible 
to postulate why both exponential and shouldered curves exist. With low LET radiation 
(shouldered curves) more repairs are possible at the lower doses, while  high LET 
radiation (exponential curves) even at low doses allows little, if any, repair. 
With these and other theories it is possible to fit survival curve data with a number 
of mathematical formulae.  However, with the numerous subtleties in the biological 
function of cells, it is impossible to predict the mechanisms of action which cause cell 26 
inactivation strictly in this manner. With the discovery of repair processes, such as the 
Q-factor, there is hope for improved, more biophysically oriented models. 
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CHAPTER 3.  CELL SURVIVAL CURVE EXPERIMENTS 
3.1 Materials and Methods 
It should be noted that this survival curve experiment was done using only 6°Co 
gamma radiation, not neutrons.  Therefore the cells were not incubated in a boron 
solution, since gamma rays would have the same effect on the cells whether or not boron 
was present. The purpose of a 6°Co survival curve is to provide a comparative curve 
against which to compare any other survival  curves (of the same cell line) performed 
under different conditions or with other types of radiation.  The results that follow will 
not be showing the BNCT effect, but rather the effect of 6°Co gamma rays on AtT-20 
cells. 
Glioma Cell Line 
The Clone AtT-20, an ACTH secreting cell line, was cloned in October, 1966 by 
G. Sato and associates. The cells are derived from a mouse pituitary tumor originally 
established in LAF1 mice by J. Furth, et al.[1].  The cells were cultured in Ham's F10 
medium, 82.5%; horse serum, 15%; fetal bovine  serum, 2.5%.  This clone has been 
carried in culture without alternative animal passage and produces ACTH at a rate of 
1000 mU /mg of cell protein per week. An inoculum of 105 viable cells/m1 will multiply 
four-fold in 10 days. These cells do not form monolayers, but instead tend to grow as 
small floating clusters. Cells appear small and rounded in solution, and slightly elongated 
when attached to a growing surface. ACTH production  continues for at least 20 passages 
after recovery from the frozen state [2]. 28 
Experimental Design and Sample Preparation 
AtT-20 cells were supplied to OSU through the Vollum Institute, Portland, OR. 
The cells were grown to near confluency in either T-75 or T-150 flasks. The cells were 
prepared into a single-cell suspension using 1  to 2 ml of trypsin and a 5 minute 
incubation at 37 °C.  The cells were then centrifuged for 5 minutes to  remove the 
residual trypsin. A dilution was then performed using Dulbecco's Modified Eagle Medium 
(D-MEM) to 20 ml. 100 pal was taken of the 20 ml solution and placed into 9.9 ml of 
isotonic solution.  The cell mixture was then counted on a Coulter Counter.  After 
determining cell density per ml, 2-3 ml of the diluted 20 ml cell solution was placed into 
a series of vials for irradiation by 6°Co gamma rays. 
Irradiation Conditions 
The irradiator used in the experiment was  a 53 Curie source 6°Co Nuclear 
Systems/Budd (model R60124). When the sources are raised, the irradiator has both a 
low flux region, where the dose ranges from 19-65 cGy/min, and a high flux region with 
a dose range of 85-181 cGy/min. Due to the structure of the irradiator, the dose rate 
depends on the position of the sample, while the total dose depends on the length of time 
each sample is exposed to the source. The calibration for the irradiator is kept current 
through a computer program which automatically accounts for the decay of the source 
over time, and continually adjusts the exposure times necessary to achieve a desired dose. 
The sample vials containing the AtT-20 cell solution were each placed separately 
into the bottom of the low flux region where they received approximately 60 cGy/min. 29 
Individual total doses received for the 7 vials were 0 (control), 100, 200, 300, 400, 500, 
600, and 800 cGy. 
Table 3-1 shows relative exposure times necessary to achieve each dose. These 
times account for the "up" and "down" transit times for the source. 
Table 3-1 6°Co y-ray Exposure Times 
EXPOSURE (cGy)  ELAPSED TIME 
(bottom of the low flux chamber)  (minutes)  (seconds) 
100  1 28 
200  3 15 
300  5  02 
400  6  49 
500  8  36 
600  10  23 
800  13  56 
Cell Plating 
Immediately following irradiation, several dilutions were made (using DMEM) of 
each sample vial prior to cell plating.  The goal of these dilutions was to arrive at a 
number of cells so that, when plated, 14 days later approximately 200 colonies would 
remain for each dose point, (assuming 70% plating  efficiency).  Following each final 
dilution, a count was made using the Coulter Counter to check plating accuracy, (except 
for experiment #1 at 600 and 800 cGy). For each of the three experiments the dilutions 
and cell plating were as follows: 30 
Table 3-2  Experiment #1 Cell Plating 
Stock Solution  Dose (cGy)  Goal # of cells to plate  Actual # of cells 
plated 
320,000 cells/ml  0  300  375 
100  300  320 
11  200  300  320 
11  400  600  750 
Of  600  4000  * 
11  800  40,000  * 
11  800  80,000  * 
* Information not available 
Table 3-3 Experiment #2 Cell Plating 
Stock Solution  Dose (cGy)  Goal # of cells to plate  Actual# of cells 
plated 
757,000 cells/ml  0  300  420 
"  100  300  450 
11  200  300  390 
11  300  450  640 
400  700  960 
500  2300  3260 
600  5000  6730 
11  800  55,000  76,700 31 
Table 3-4 Experiment #3 Cell Plating 
Stock Solution  Dose (cGy)  Goal # of cells to plate  Actual # of cells 
plated 
2,345,000 cells/ml  0  300  260 
100  600  575 
200  600  510 
to  300  1200  910 
ft  400  3200  2460 
es  500  15,000  9460 
600  56,000  45,600 
800  700,000  532,000 
Following the final dilution, each of the samples was split into five separate 10 
cm plating dishes, with the appropriate number of cells per dose point plated in each dish. 
The two main reasons for this step was 1) to test the accuracy of plating techniques, and 
2) to ensure that no dose point would be eliminated should contamination occur. (Plates 
that became contaminated were eliminated from the experiment.)  The Coulter Counter 
is accurate to a much higher degree than the pipettes used  to draw the cells from the 
vials, so the goal number of cells to plate and the actual number  of cells plated are 
different. The plates were then incubated at 37 °C for 14 days.  The cell medium (D­
MEM, 10% FCS + penn-strep) was changed every third day for the two week period. 
Colony Counting 
After 14 days, the remaining plates were removed from the incubator. The cells 
were  drained of media and washed with phosphate buffered saline (PBS). A 10% 
formaldehyde solution was then placed into each plate for the purpose of "fixing" the cells 
to the plate. After rinsing with PBS a second time, a small amount of 5% Giemsa stain 32 
was placed onto each plate, remaining in contact with the cells for approximately five 
minutes. The cells were then washed with doubly distilled water to remove the excess 
stain. 
With the colonies now visible, representative plates for each dose point  were 
examined under an Olympus (model CK 2) inverted microscope  at high power to 
determine what a viable colony looks like to the naked eye.  It was determined that a 
viable colony is generally a colony of 50 cells  or more, a large percentage of which 
appear "normal". 
The first set of plates (from experiment #1) was counted by stretching a piece of 
Parafilm over the underneath side of each plate, and with a permanent pen marking each 
colony as it was counted. This method seemed to work fine; however, the next two sets 
of plates (experiments #2 and #3) were counted using  an automatic colony counter 
(BANTEX 900A). The counter set-up includes a 32 watt circular fluorescent light source, 
a 150 mm grid on which to set the plates, a 1.5X magnifier, and a porous tip electronic 
pen that not only marks each colony, but automatically registers a count, sounding a tone 
for each, when contact with the counting surface is made. This method was time-saving 
as well as being highly accurate and precise. 
3.2 Results 
Colony Growth and Development 
A total of 40 plates were seeded with cells following irradiation (five per dose 
point) and incubated for 14 days. Each of the plates was examined daily to determine if 
any contamination were present. During the latter phases of growth, approximately 25% 33 
of the plates showed some form of contamination. If the contamination was minimal, the 
plates could often be saved, but several plates were completely overgrown and had to be 
thrown out. Since contamination was kept under control to as great a degree as possible, 
each data point was accurately represented, with a few exceptions. The 14-day growth 
period seemed ideal, since within that time the colonies had grown large enough to be 
seen with the naked eye. 
Colony Counting 
Each of the five plates per dose point was counted and an average number of 
colonies per dose point calculated. The % survival (normalized to control) was calculated 
by dividing the % survival for each of the dose points by the % survival for the control, 
i.e., by the plating efficiency. The results for each of the experiments were as follows: 
Table 3-5 Experiment #1 Results 
%  survival 
normalized 
Dose (cGy)  # of cells plated  Ave. # colonies  % survival  to control 
0  365  220±09  60.3  1.00
 
100  320  194±10  60.6  1.00
 
200  320  183  57.2  0.95
 
400  750  167  22.2  0.37
 
600  4000  158±11  3.9  0.065
 
800  40,000  142±11  0.35  0.0058
 34 
Table 3-6 Experiment #2 Results 
%  survival 
normalized 
Dose (cGy)  # of cells plated  Ave. # colonies  % survival  to control 
0  420  279±20  66.4  1.00 
100  450  151±21  33.6  0.51 
200  390  130±20  33.3  0.50 
300  640  107±19  16.7  0.25 
400  960  60±15  6.3  0.095 
500  3260  43±11  1.3  0.020 
600  6730  24±11  0.31  0.0047 
800  76,700  11±07  0.014  0.00021 
Table 3-7 Experiment #3 Results 
%  survival 
normalized 
Dose (cGy)  # of cells plated  Ave. # colonies  % survival  to control 
0  260  212±17  82.2  1.00
 
100  575  417±24  72.5  0.88
 
200  510  275±24  54.1  0.66
 
300  910  122±20  13.4  0.16
 
400  2460  190±23  7.7  0.094
 
500  9460  264±22  2.8  0.034
 
600  45,600  238±26  0.5  0.006
 
800  532,000  219±25  0.04  0.0005
 
Survival Curves 
The three survival curves generated from these colony counts are typical of low 
LET radiation (X-ray or gamma ray) exposure. There is a near zero slope region for low 
doses, a shoulder, and an exponential region for high doses (See Figures 3-1, 3-2 and 3­
3). 35 
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Table 3-8 shows the relationship between each of the three parameters (Do, Dq, and 
n) for each of the three experiments. 
Table 3-8  Comparative Cell Survival Curve Parameters for Experiments 1, 2, and 3 
Experiment #  Dq (cGy)  D. (cGy)  n 
1  252  115  9
 
2  187  75  12
 
3  175  85  8
 
As can be noted from Figures 3-1, 3-2 and 3-3, (as well as from Table 3-8), the 
parameters of the three curves are relatively close in numerical value. Figure 3-4 shows 
the relationship between all three cell survival curves, and despite their differences, the 
slope of each is quite consistent with the others. However, since curves 2 and 3 show a 
higher degree of similarity to each other than to  curve 1, Figure 3-5 is a combined 
exponential fit of curves 2 and 3.  This final curve is therefore representative of a low 
LET radiation cell survival curve for the AtT-20 cell line. 
Calculation of Statistical Errors 
Calculation of the statistical errors for curves 2 and 3 was done through the use 
of a binomial distribution, where the statistical error per dose point is shown by 39 
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(an exponential fit between curves 2 and 3) 41 
where 
the total number of colonies per dose point P 
n 
9 = (1 -P) 
is = the total number of cells plated per dare point 
If the formula is written as 
p ±11(1-p)(number of colonies) 
it can be noted that as p gets very small, the error approaches 
Vnumber of colonies 
The determination that a binomial distribution was appropriate was made upon evaluation 
of the experiment: 
1.	  The experiment consists of n identical trials. 
2.	  Each trial results in one of two possible outcomes (success or failure). 
3.	  The probability of success on a single trial is equal  to p and remains the same
from trial to trial. The probability of a failure is equal to (1-p) = q. 
4.	  The trials are independent. 
5.	  The random variable of interest is the number of successes observed during the
n trials. 42 
Table 3-9 contains the combined statistical errors for each dose point of experiments 2
 
and 3.
 
Table 3-9 The Combined Statistical Errors of Experiments 2 and 3
 
Dose (cGy)  Error (16)
 
0  4.55 x 104
 
100  3.87 x 10-3
 
200  3.70 x 10-3
 
300  1.95 x 10-3
 
400  9.59 x 10-4
 
500  2.83 x 10-4
 
600  5.08 x 10-5
 
800  4.93 x 10-6
 
3.3 Discussion 
The OSU BNCT 6°Co survival curve experiments were carried out to demonstrate 
the effects of various doses of low LET radiation (X-rays or gamma rays) on a particular 
mammalian cell line. According to theories mentioned previously, survival curves of this 
nature should be of the sigmoid shape, with a zero-slope region, a shoulder and an 
exponential region. What was seen in the experiments was in fact a very reasonable 
representation of a low LET radiation survival curve. The results were quite repeatable, 
with slight exception to curve #1. 
In the first experiment six dose points were measured, which left a few areas of 
the curve slightly open to suggestion.  While the curve definitely tends to follow the
 
shape of a low LET survival curve, viable plates for two of the dose points (200 and 400
 
cGy) were reduced to one plate due to contamination.  Statistically, these points are not
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extremely meaningful. However since both points fall within the general shape of the 
curve, they are assumed to be close to what an average of the dose point might have 
been.  In experiment 2, two additional dose points (300 and 500 cGy) were included to 
smooth out the curve. These dose points proved to be quite informative and were also 
included in experiment 3. 
The cell handling techniques also improved somewhat in the later experiments. 
For example, trypsinization in the first experiment did not seem complete, and the cells 
remained in clusters after being removed from the flasks.  This could explain the 
difference in the order of magnitude of cell killing observed between the first experiment 
and the second two. Since the cells remained in clusters throughout the experiment, they 
were therefore irradiated as clusters. When irradiated, a cluster of cells would not react 
the same as a single cell.  It would in fact act as a very resistant cell, since it would 
undoubtedly take many more hits to inactivate an entire cluster than it would to kill a 
single cell. These clusters, when plated, would therefore have a much greater chance of 
survival than a single cell, since any one surviving cell could form a colony.  It is 
believed to be mainly for this reason that the first curve shows differing results from the 
second and third curves. 
In addition, some of the equipment used in the first experiment  was not as 
technologically advanced as in the later experiments. For example, the laminar flow hood 
under which the cells were handled did not have an ultraviolet lamp installed during the 
first experiment. (UV-C emitting lamps serve as an extra precaution against any spores 
or other contaminants that may enter the hood when its filter system is not in use.) It is 44 
possible that the decreased amount of contamination seen in experiments 2 and 3 was due 
to the addition of this lamp. A propane gas flame was also installed prior to the second 
and third experiments. The tops of all bottles, flasks and the tips of pipettes were flamed 
before coming in contact with the cells. A vacuum system was also created and used for 
the purpose of quickly, safely and completely removing liquids from the cells, (e.g., cell 
media changes, cell staining, etc.).  Liquid removal in the first experiment consisted of 
hand pipetting into a waste receptacle. 
Colony counting changed drastically between the first and second two experiments. 
As mentioned before, the original method used consisted of a piece of parafilm stretched 
across the underside of the plates, and marking off colonies one at a time with a 
permanent marker.  Although this method did seem to be fairly accurate, it would have 
been more so had a light source (other than room light) been availalble.  The colony 
counter used in the second and third experiments included  a bright light source, a 
counting grid, a magnifier, and an electronic  pen which marked and counted 
simultaneously. It is not difficult to believe that this method was more accurate. 
Although the second and third curves look to be nearly identical on paper, there 
were some differences in cell plating techniques between the two.  In the second 
experiment, a slightly lower number of cells was plated per dose point than would have 
been ideal.  Since the cells irradiated in the second experiment  were completely 
trypsinized into a single-cell solution, the the kill ratio between cells plated  and cells 
surviving increased more than anticipated. Therefore, the number of colonies per plate 
was slightly lower than expected.  However, for the final experiment a much greater 45 
number of cells was seeded per plate in order to arrive at approximately  a 200 colony per 
plate number. 
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CHAPTER 4. CONCLUSIONS AND RECOMMENDATIONS
 
This chapter consists of a brief explanation of future plans for cell survival curves 
involving demonstration of a BNCT effect, as well as a general summary of the 6°Co cell 
survival curve experiments. 
4.1  Futtue Survival Curve Experiments 
Since the completion of AtT-20 "Co survival  curves, procedures have begun for 
determining cell survival curves in the Oregon State TRIGA Reactor  (OSTR).  (The 
OSTR is a 1.1 MW Mark II research reactor.) The basic cell procedures will involve a 
short incubation in a solution containing a 10B cage and hormone conjugate (as described 
previously). To determine a BNCT effect, the cells incubated in the '°B solution will be 
compared to a control group incubated in a non-conjugated solution, but exposed to the 
identical neutron field, as well as a control group not incubated nor exposed to neutrons. 
The exposures will consist of 1, 2, 3, 4 and 5.5 MW-minutes  in the thermal column of 
the reactor. The thermal column is an area of the reactor where the potential exists for 
maximal thermal neutron flux with a minimal epithermal and fast neutron component, as 
well as a relatively low gamma ray flux. 
There have been many experiments in the OSTR involving boronylated AtT-20 
cells, and a BNCT effect has been observed [1]. However, the task at hand is to generate 
cell survival curves demonstrating the BNCT effect. 47 
4.2  Summary 
With successful human clinical trials in Japan, hope has been renewed in BNCT 
as an alternative treatment for cancer. Originally thought to be useful in treating deep-
seated gliomas and malignant melanomas, continuing research has provided some initial 
evidence favoring the use of BNCT in many other types of neoplasms, specifically 
breast, prostate, and endocrine cancers. OSU researchers, in collaboration with OHSU, are 
currently determining the efficacy of BNCT as a treatment for pituitary tumors, an 
endocrine cancer. 
In order to clearly demonstrate a BNCT effect, it is necessary to generate cell 
survival curves through in vitro cell irradiations with  neutrons.  It is also necessary to 
show a comparitive curve generated through in vitro cell irradiations with "Co  gamma 
rays, a low LET radiation. 
A cell survival curve is a method of demonstrating the biological  effects of 
radiation through in vitro irradiation of cells.  Generally a number of dose points  are 
covered (including 0), and as dose increases, cell survival decreases.  The shape of these 
curves is of two basic forms: exponential, seen as a result of high LET radiation such 
as neutrons, and shouldered, typical of low LET radiation such  as 'Co gamma-rays. 
Several theories exist which attempt to explain the radiobiological phenomena involved 
in cell survival curve interpretation. The internal mechanisms responsible for whether or 
not cells survive irradiation are complex, and whether any of the theories is correct is not 
known. However, predictability in cell lines in response to specific radiations can be 
shown through the cell survival curve. 48 
With the completion of the 6°Co cell survival curves, and the results thereof, the 
OSU/OHSU BNCT project  will  next focus on generating  cell  survival  curves 
demonstrating a BNCT effect. 
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